Company Overview
Probionic Corp. ? Revolutionizing Health Through Microbiome Innovation
At Probionic Corp., we are dedicated to transforming the future of healthcare with groundbreaking microbiome solutions. For over 25 years, our relentless research and passion have driven us to pioneer microbiome technologies that address the root causes of chronic diseases. Today, we stand at the forefront of the global microbiome field, armed with a powerful, internationally patented strain of skin immune-regulating lactic acid bacteria (Lactobacillus sakei Probio65™) and a bold mission: to elevate human health and quality of life worldwide.
Probionic’s patented L. sakei Probio65™ ? a clinically validated strain for its immune-balancing properties ? represents a leap forward in microbiome science. Our innovation has now advanced beyond traditional applications: having successfully passed US-FDA IND (Investigational New Drug) requirements, we are currently conducting Phase 2 clinical trials at a leading U.S. university hospital to develop this strain into a first-in-class microbiome drug for chronic inflammatory conditions.
At Probionic Corp., we are dedicated to transforming the future of healthcare with groundbreaking microbiome solutions. For over 25 years, our relentless research and passion have driven us to pioneer microbiome technologies that address the root causes of chronic diseases. Today, we stand at the forefront of the global microbiome field, armed with a powerful, internationally patented strain of skin immune-regulating lactic acid bacteria (Lactobacillus sakei Probio65™) and a bold mission: to elevate human health and quality of life worldwide.
Probionic’s patented L. sakei Probio65™ ? a clinically validated strain for its immune-balancing properties ? represents a leap forward in microbiome science. Our innovation has now advanced beyond traditional applications: having successfully passed US-FDA IND (Investigational New Drug) requirements, we are currently conducting Phase 2 clinical trials at a leading U.S. university hospital to develop this strain into a first-in-class microbiome drug for chronic inflammatory conditions.
